Anna Maria Wirsing

Dr. Anna Maria Wirsing


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
AWAnna Maria Wirsing
Anna Maria Wirsing
OROddveig G. Rikardsen
Oddveig G. Rikardsen
SSSonja E. Steigen
Sonja E. Steigen
LULars Uhlin-Hansen
Lars Uhlin-Hansen
EHElin Hadler-Olsen
Elin Hadler-Olsen

14 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AWAnna Maria Wirsing
Anna Maria Wirsing
IBInger-Heidi Bjerkli
Inger-Heidi Bjerkli
SSSonja Eriksson Steigen
Sonja Eriksson Steigen
OROddveig Rikardsen
Oddveig Rikardsen
SMSynnøve Magnussen
Synnøve Magnussen
EHElin Hadler-Olsen
Elin Hadler-Olsen
The Pathology Atlas is an open-access database that reports the prognostic value of protein-coding transcripts in 17 cancers, including head and neck cancer. However, cancers of the various head and neck anatomical sites are specific biological entities. Thus, the aim of the present study was to validate promising prognostic markers for head and neck cancer reported in the Pathology Atlas in oral tongue squamous cell carcinoma (OTSCC). We selected three promising markers from the Pathology Atlas (CALML5, CD59, LIMA1), and analyzed their prognostic value in a Norwegian OTSCC cohort comprising 121 patients. We correlated target protein and mRNA expression in formalin-fixed, paraffin-embedded cancer tissue to five-year disease-specific survival (DSS) in univariate and multivariate analyses. Protein expression of CALML5 and LIMA1 were significantly associated with five-year DSS in the OTSCC cohort in univariate analyses (p = 0.016 and p = 0.043, respectively). In multivariate analyses, lymph node metastases, tumor differentiation, and CALML5 were independent prognosticators. The prognostic role of the other selected markers for head and neck cancer patients identified through unbiased approaches could not be validated in our OTSCC cohort. This underlines the need for subsite-specific analyses for head and neck cancer.